CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
Oral azithromycin +1 moredrug
Likely dose
Oral azithromycin 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02911935
NCT02911935Phase 3Completed
CompareCT.gov

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

Washington University School of Medicine·interventional·Posted Sep 22, 2016·Updated Jun 7, 2022

In Brief

A Phase 3 clinical trial evaluating Oral azithromycin and Placebo for Respiratory Syncytial Virus, Bronchiolitis. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus, Bronchiolitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 22, 2016
Enrollment StartNov 1, 2016
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.8 years ago

Interventions

Oral azithromycindrug

Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days

Placebodrug

Placebo suspension